Google DeepMind's AlphaGenome 2 release
- Google DeepMind released AlphaGenome 2 on November 11, 2026, a conditional genomic model that takes both a DNA sequence and a target cell type as input and identifies causal variants in 30% of cases versus 16% for the prior model on the TenK10K immune cell dataset.
- As a demonstration, DeepMind reported it reproduced a published finding that a variant drives inflammatory bowel disease by overactivating the ETS2 gene specifically in gut macrophages.
- Separately, researchers have applied the original AlphaGenome to Alzheimer's disease research: one study nominated candidate causal genes in a GWAS of argyrophilic grain disease, and another found an AD risk variant may alter transcription and splicing of the Fc receptor gene FCER1G.
- API outputs cannot be used to train other machine learning models, and commercial access is available via Google Cloud.
The model addresses a core challenge in human genetics: explaining how a single-letter DNA change can affect disease in one cell type while sparing others. Independent application of the original AlphaGenome to Alzheimer's research shows the framework is being adopted for mechanistic analysis of GWAS variants in neurodegenerative disease.